AIDS and haemophilia: morbidity and morality in a well defined population.

Jones, Pat; Hamilton, Peter J.; Bird, Geoffrey L.; Fearns, M; Oxley, Aaron; Tedder, Richard S.; Cheingsong-Popov, Rachanee; Codd, A. A.

doi:10.1136/bmj.291.6497.695

Cited by 73 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown the high incidence of non-A, non-B hepatitis (NANBH) in patients receiving such concentrates for the first time [1,2], and other reports document the transmission of hepatitis B [3] and HIV [4], Heat treatment is an effective means of inactivation of many viruses and can be applied to the lyophilised product. However, experi ence with dry heated factor VIII concentrates suggests that transmission of NANBH is not eliminated by heating for 72 h at 60°C [5] and that, despite the fact that HIV has been shown to be rapidly inactivated at 60 °C in some circum stances [6], patients receiving at least one factor VIII con centrate heated in the lyophilised state for 30 h at 60 °C have seroconverted [7].…”

Section: Introductionmentioning

confidence: 99%

Severely Heated Therapeutic Factor Vili Concentrate of High Specific Activity

Winkelman¹,

Owen²,

Evans³

et al. 1989

Vox Sanguinis

View full text Add to dashboard Cite

A new method for the manufacture of a heated factor VIII concentrate of high specific activity (2-6 IU factor VIII:C/mg protein) has been developed. Addition of heparin to cryoprecipitate extract at acid pH precipitated fibrinogen and fibronectin. Factor VIII was then recovered from the supernatant by precipitation with glycine and sodium chloride. After re-solution and desalting on Sephadex G-25, the concentrate was sterile-filtered and lyophilised. The dried product was stable to heating in the final container at 80°C for 72 h. Data from 25 consecutive batches of concentrate prepared from 1,200-1,500 kg plasma pools are presented. The mean final yield of heated product was 190 IU factor VIII:C/kg plasma. The concentrate has been found to be safe and effective in clinical use.

show abstract

Section: Introductionmentioning

confidence: 99%

Severely Heated Therapeutic Factor Vili Concentrate of High Specific Activity

Winkelman¹,

Owen²,

Evans³

et al. 1989

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…Studies of female partners of men with acquired immunodeficiency syndrome (AIDS) or AIDSrelated conditions (ARC) have found high seropositivity rates, from 36 per cent to 71 per cent,9l1 whereas studies of mostly asymptomatic female partners of seropositive hemophiliacs report much lower rates, from 7 per cent to 15 per cent. [12][13][14] The differences in apparent transmission of HIV in these studies are difficult to explain by sexual practices alone and suggest variation in the infectiousness of the HIV carrier or in the susceptibility to infection of the partner. We report here on an analysis of risk factors for seropositivity to HIV antibody in a group of homosexual men who were regular sexual partners of men who developed AIDS.…”

Section: Introductionmentioning

confidence: 99%

Time of exposure and risk of HIV infection in homosexual partners of men with AIDS.

Osmond¹,

Bacchetti²,

Chaisson³

et al. 1988

Am J Public Health

View full text Add to dashboard Cite

We interviewed, and tested for HIV antibody, 117 homosexual men who had been regular sexual partners of men who developed acquired immunodeficiency syndrome (AIDS); 85 tested seropositive. Receptive anal intercourse with the index AIDS case and number of different sexual partners with whom subjects were anally receptive were both risk factors. Controlling for the number of partners with whom subjects were anally receptive, we found that the odds ratio of receptive anal intercourse with the case was infinite IntroductionThe epidemiologic evidence for sexual transmission of human immunodeficiency virus (HIV) among homosexual men is conclusive. Receptive anal intercourse, in particular, has consistently been reported as the sexual behavior most

show abstract

“…The earliest infection occurred in 1981; however, most patients were infected during 1983 and 1984 [2], 6-24 months prior to the study. The number of seropositive patients with overt clinical abnormalities (28 %) was only slightly less than the 39% reported from the Newcastle Hemophilia Reference Centre (UK) [3] ; however, the proportion of patients with significant physical incapacity was very low (5%), and only one patient has so far developed AIDS. All patients with clinical signs or symptoms had reduced T-helper cells and T-helper/ suppressor ratios.…”

Section: Discussionmentioning

confidence: 90%

“…Clinical features of HTLV-111 infection have also been described [3] in hemophiliacs, including acquired immune deficiency syndrome (AIDS), lymphadenopathy syndrome, and immune thrombocytopenia; however, the frequency of significant symptomatology has not been well established. The role of this virus in the etiology of immune dysfunction in hemophiliacs also remains controversial.…”

Section: Introductionmentioning

confidence: 96%

Spectrum of HTLV‐III infection in a hemophilic cohort treated with blood products from a single manufacturer

McGrath

Spelman²,

Barnett

et al. 1986

American J Hematol

View full text Add to dashboard Cite

One hundred fifty-eight hemophilia A, B, and von Willebrand disease (VWD) patients treated with clotting factor concentrates from a single manufacturer were tested for antibody to the human T-lymphotropic virus type III (HTLV-III). Antibody was detected in 63% and 40% of those with severe hemophilia A and B, respectively, 12% and 0% of those with mild hemophilia A and B, and two patients with recessive VWD. Forty-two antibody-positive and 20 antibody-negative patients were studied for clinical and laboratory features of infection. Eleven seropositive patients had clinical signs of infection including Pneumocystis carinii pneumonia, lymphadenopathy, splenomegaly or diarrhea; however, only one patient had developed acquired immune deficiency syndrome (AIDS), and only two had significant impairment of their performance status. Thirty-one patients remained totally asymptomatic. Eight patients had a history suggestive of acute HTLV-III infection. Thrombocytopenia was observed in 18% of seropositive patients, lymphopenia in 60%, depressed T-helper cells in 43%, reduced T-helper:T-suppressor ratios (TH:TS) in 33%, and elevated platelet-bound immunoglobulin in 53%. The antibody-negative group had normal T-helper cell levels (except one patient) and TH:TS ratios, and normal platelet immunoglobulin levels. Both groups demonstrated a significant elevation of immunoglobulin levels and a high prevalence of antinuclear factor and antismooth muscle antibodies. The mean level of IgG was significantly higher in the antibody-positive group. This study confirms the correlation between HTLV-III infection and reduced T-helper cells in hemophiliacs but demonstrates a low incidence of clinical symptomatology. There was evidence of polyclonal B-cell hyperactivity in the antibody-negative group as well as the seropositive group.

show abstract

AIDS and haemophilia: morbidity and morality in a well defined population.

Cited by 73 publications

References 18 publications

Severely Heated Therapeutic Factor Vili Concentrate of High Specific Activity

Severely Heated Therapeutic Factor Vili Concentrate of High Specific Activity

Time of exposure and risk of HIV infection in homosexual partners of men with AIDS.

Spectrum of HTLV‐III infection in a hemophilic cohort treated with blood products from a single manufacturer

Contact Info

Product

Resources

About